Skip to main content
SpringerLink
Log in
Book cover

Kidney Cancer pp 385–402Cite as

Emerging Agents in Renal Cell Carcinoma

  • Chapter

  • 1031 Accesses

Abstract

The landscape of therapy for metastatic renal cell carcinoma (mRCC) has changed drastically over the past decade, hinging largely on the approval of seven targeted agents. While this undoubtedly represents a milestone in the treatment of this disease, it is critical to bear in mind that the seven agents fall broadly within two mechanistic categories: (1) vascular endothelial growth factor (VEGF)-directed therapies (sunitinib, sorafenib, pazopanib, axitinib, and bevacizumab) and (2) inhibitors of the mammalian target of rapamycin (mTOR; everolimus and temsirolimus). Other chapters in this book will delineate agents that are consistent with this paradigm. Ultimately, however, the research community will need to look toward agents that target distinct signaling axes or employ novel mechanisms to augment antitumor immunity. The current chapter explores a range of emerging therapies – ranging from vaccine therapy to cytotoxic chemotherapy – that may add to the current armamentarium for mRCC.

Support: Dr. Pal’s efforts are supported by CBCRP 15IB-0140 (California Breast Cancer Research Program Junior IDEA Award) and NIH K12 2K12CA001727-16A1.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1996) Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 14(8):2410–2411

    CAS  PubMed  Google Scholar 

  2. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696

    CAS  PubMed  Google Scholar 

  3. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296

    Article  CAS  PubMed  Google Scholar 

  4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, The TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134

    Article  CAS  PubMed  Google Scholar 

  5. Escudier BJ, Bellmunt J, Negrier S, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, on behalf of the AVOREN Investigators (2009) Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-{alpha}2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meet Abstr) 27(15S):5020

    Google Scholar 

  6. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IGH, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ, The Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281

    Article  CAS  PubMed  Google Scholar 

  7. Kay A, Motzer R, Figlin R, Escudier B, Oudard S, Porta C, Hutson T, Bracarda S, Hollaender N, Urbanowitz G, Ravaud A (2009) Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). Presented at the 2009 Genitourinary Cancers Symposium (Abstr 278)

    Google Scholar 

  8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068

    Article  CAS  PubMed  Google Scholar 

  11. Pal SK, Figlin RA (2010) Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape. Nat Rev Clin Oncol 7(7):362–363

    Article  CAS  PubMed  Google Scholar 

  12. Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor†targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799

    Article  CAS  PubMed  Google Scholar 

  13. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422

    Article  CAS  PubMed  Google Scholar 

  14. Healey D, Gamble AH, Amin A, Cohen V, Logan T, Nicolette CA (2010) Immunomonitoring of a phase I/II study of AGS-003, a dendritic cell immunotherapeutic, as first-line treatment for metastatic renal cell carcinoma. ASCO Meet Abstr 28(15 Suppl):e13006

    Google Scholar 

  15. Amin A, Dudek A, Logan T, Lance RS, Holzbeierlein JM, Williams WL, Jain R, Chew TG, Nicolette CA, Figlin RA, AGS-003-006 Study Group (2010) A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. J Clin Oncol (Meet Abstr) 28(15 Suppl):4588

    Google Scholar 

  16. NCT01582672: Phase 3 trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment of advanced renal cell carcinoma (RCC) (ADAPT). Available at http://www.clinicaltrials.gov. Last accessed 15 Dec 2013

  17. Singh-Jasuja H, Walter S, Weinschenk T, Mayer A, Dietrich PY, Staehler M, Stenzl A, Stevanovic S, Rammensee H, Frisch J (2007) Correlation of T-cell response, clinical activity and regulatory T-cell levels in renal cell carcinoma patients treated with IMA901, a novel multi-peptide vaccine. ASCO Meet Abstr 25(18 Suppl):3017

    Google Scholar 

  18. Reinhardt C, Zdrojowy R, Szczylik C, Ciuleanu T, Brugger W, Oberneder R, Kirner A, Walter S, Singh H, Stenzl A (2010) Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC). ASCO Meet Abstr 28(15 Suppl):4529

    Google Scholar 

  19. Singh H, Hilf N, Mendrzyk R, Maurer D, Weinschenk T, Kirner A, Frisch J, Reinhardt C, Stenzl A, Walter S (2010) Correlation of immune responses with survival in a randomized phase II study investigating multipeptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC). ASCO Meet Abstr 28(15 Suppl):2587

    Google Scholar 

  20. NCT01265901: A randomized, controlled phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma. Available at http://clinicaltrials.gov/ct2/show/NCT01265901?term=IMA-901&rank=2. Last accessed 22 Oct 2012

  21. Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E (2011) A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 60(2):261–271

    Article  CAS  PubMed  Google Scholar 

  22. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J (1995) Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129(1):255–265

    Article  CAS  PubMed  Google Scholar 

  23. Kraus S, Abel PD, Nachtmann C, Linsenmann H-J, Weidner W, Stamp GWH, Chaudhary KS, Mitchell SE, Franke FE, Lalani E-N (2002) MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum Pathol 33(1):60–67

    Article  CAS  PubMed  Google Scholar 

  24. Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B (2003) Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5(8):690–699

    Article  CAS  PubMed  Google Scholar 

  25. Schmidt M, Volz B, Schroff M, Kapp K, Kleuss C, Tschaika M, Wittig B (2010) Safety data of MGN1601, a tumor vaccine, made of allogeneic, transfected, and irradiated tumor cells in combination with an immunomodulator for the treatment of metastatic renal cell carcinoma. ASCO Meet Abstr 28(15 Suppl):e15104

    Google Scholar 

  26. NCT01265368: A phase 1/2, proof-of-principle, multi-center, open-label, single-arm, non-randomized clinical study to assess safety and efficacy of a tumor vaccine consisting of genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination With a DNA-based double stem loop immunomodulator in patients with advanced renal cell carcinoma (ASET study). Available at http://www.clinicaltrials.gov. Last accessed 17 Mar 2011

  27. Bennouna J, Bompas E, Neidhardt E, Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Négrier S (2008) Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57(11):1599–1609

    Article  CAS  PubMed  Google Scholar 

  28. Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T (2001) Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother 50(3):115–124

    Article  CAS  PubMed  Google Scholar 

  29. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704

    Article  CAS  PubMed  Google Scholar 

  30. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED (2004) Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101(49):17174–17179

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Choueiri TK, Fishman MN, Escudier BJ, Kim JJ, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman LJ, Fong L, Drake CG, Cohen LJ, Srivastava S, Jure-Kunkel M, Hong Q, Kurland JF, Sznol M (2014) Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. ASCO Meeting Abstracts 32(5 Suppl)

    Google Scholar 

  32. Drake CG, McDermott DF, Sznol M, Choueiri TK, Kluger HM, Powderly JD, Smith DC, Sankar V, Gutierrez AA, Wigginton JM, Kollia G, Gupta AK, Atkins MB (2013) Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. ASCO Meet Abstr 31(15 Suppl):4514

    Google Scholar 

  33. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel T, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Waxman I, Lambert A, Hammers HJ (2014) Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. ASCO Meeting Abstracts 32 (5 Suppl)

    Google Scholar 

  34. NCT01668784: Study of nivolumab (BMS-936558) vs. everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma (CheckMate 025). Available at http://www.clinicaltrials.gov. Last accessed 20 Feb 2014

  35. Hammers HJ, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermot DF, Razak ARA, Pal SK, Voss MH, Sharma P, Kollmannsberger CK, Heng DYC, Spratlin JL, Shen Y, Kurland JF, Gagnier P, Amin A (2014) Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 32(5 Suppl)

    Google Scholar 

  36. Manoukian G, Hagemeister F (2009) Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 9(11):1445–1451

    Article  CAS  PubMed  Google Scholar 

  37. van derVliet HJJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley MA (2007) Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 13(7):2100–2108

    Article  Google Scholar 

  38. Atchison E, Eklund J, Martone B, Wang L, Gidron A, Macvicar G, Rademaker A, Goolsby C, Marszalek L, Kozlowski J, Smith N, Kuzel TM (2010) A pilot study of Denileukin Diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic Renal Cell Carcinoma (RCC). J Immunother 33(7):716–722

    Article  CAS  PubMed  Google Scholar 

  39. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF et al (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52(12):3317–3322

    CAS  PubMed  Google Scholar 

  40. Fumagalli L, Lissoni P, Felice GD, Meregalli S, Valsuani G, Mengo S, Rovelli F (1999) Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 80(3–4):407–411

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B (2010) A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 103(8):1154–1162

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Nakaigawa N, Yao M, Baba M, Kato S, Kishida T, Hattori K, Nagashima Y, Kubota Y (2006) Inactivation of von hippel-lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res 66(7):3699–3705

    Article  CAS  PubMed  Google Scholar 

  43. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJM, Walther MM, Tsui L-C, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16(1):68–73

    Article  CAS  PubMed  Google Scholar 

  44. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R (2013) Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 31(2):181–186

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin WG, Dutcher JP (2014) A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 25:1603–1608

    Article  CAS  PubMed  Google Scholar 

  46. NCT01865747: A study of cabozantinib (XL184) vs everolimus in subjects with metastatic renal cell carcinoma (METEOR). Available at http://www.clinicaltrials.gov. Last accessed on 20 Feb 2014

  47. Goldberg J, Demetri GD, Choy E, Rosen L, Pappo A, Dubois S, Geller J, Chai F, Ferrari D, Wagner AJ (2009) Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. ASCO Meet Abstr 27(15S):10502

    Google Scholar 

  48. Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Takahashi M, Kanayama H (2008) Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest 55(1,2):106–111

    Article  PubMed  Google Scholar 

  49. Michieli P, Basilico C, Pennacchietti S, Maffe A, Tamagnone L, Giordano S, Bardelli A, Comoglio PM (1999) Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18(37):5221–5231

    Article  CAS  PubMed  Google Scholar 

  50. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O’Connor DS, Li F, Altieri DC, Sessa WC (2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/Survivin pathway. J Biol Chem 275(13):9102–9105

    Article  CAS  PubMed  Google Scholar 

  51. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun J-R, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6(5):507–516

    Article  CAS  PubMed  Google Scholar 

  52. Bullock AJ, Zhang L, O’Neill AM, Percy A, Sukhatme V, Mier JW, Atkins MB, Bhatt RS (2010) Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). J Clin Oncol (Meet Abstr) 28(15 Suppl):4630

    Google Scholar 

  53. NCT00982657: A phase Ib/II, multicenter, trial Of CVX-060, a selective angiopoietin-2 (ANG-2) binding, anti-angiogenic COVX-body, in combination with sunitinib in patients with advanced renal cell carcinoma. Available at http://www.clinicaltrials.gov. Last accessed 26 Mar 2011

  54. Rosen LS, Mendelson DS, Cohen RB, Gordon MS, Goldman JW, Bear IK, Byrnes B, Perea R, Schoenfeld SL, Gollerkeri A (2010) First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. ASCO Meet Abstr 28(15 Suppl):2524

    Google Scholar 

  55. Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SJ, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcon BL, McDonald DM, Li L, Boone T, Kendall R, Radinsky R, Oliner JD (2010) Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9(10):2641–2651

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun Y-N, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS (2009) Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21):3557–3565

    Article  CAS  PubMed  Google Scholar 

  57. Rini BI, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Kracht K, Sun Y, Puhlmann M, Escudier B (2011) AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study. Presented at the 2011 Genitourinary Cancers Symposium [Abstr 309]

    Google Scholar 

  58. Frost A, Steinbild S, Büchert M, Unger C, Christensen O, Voliotis D, Heinig R, Mross K Phase I trial of BAY 73-4506, a kinase inhibitor that targets oncogenic and angiogenic kinases, in patients with advanced solid tumors. Presented at the 2007 AACR-NCI-EORTC molecular targets and cancer therapeutics in San Francisco [Abstr B85]

    Google Scholar 

  59. Shimizu T, Tolcher A, Patnaik A, Papadopoulos K, Christensen O, Lin T, Blumenschein G (2010) Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. J Clin Oncol 28(15S):Abstract 3035

    Google Scholar 

  60. Strumberg D, Scheulen ME, Frost A, Büchert M, Christensen O, Wagner A, Heinig R, Fasol U, Mross K (2009) Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC). J Clin Oncol 27(15S):Abstract 3560

    Google Scholar 

  61. Eisen T, Joensuu H, Nathan P, Harper P, Wojtuhiewicz, Nicholson S, Bahl A, Tomczak P, Wagner A, Quinn D (2009) Phase II trial of the oral multikinase inhibitor regorafenib (BAY 73-4506) as first-line therapy in patients with metastatic or unresectable renal cell cancer (RCC). EJC Suppl 7(424):Abstract 7105

    Google Scholar 

  62. Jeffers M, Quinn DI, Joensuu H, Nathan P, Harper PG, Wojtukiewicz M, Nicholson S, Bahl A, Tomczak P, Eisen T (2009) Identification of plasma biomarkers for the multikinase inhibitor regorafenib (BAY 73-4506) in patients with renal cell carcinoma (RCC). EJC Suppl 7(424):Abstract 7105

    Google Scholar 

  63. Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107(11):2609–2616

    Article  CAS  PubMed  Google Scholar 

  64. Amato RJ, Hernandez-McClain J, Saxena S, Khan M (2008) Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 31(3):244–249, 210.1097/COC.1090b1013e31815e31451f

    Article  CAS  PubMed  Google Scholar 

  65. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30(8):825–830

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. NCT01218555: Phase I study of everolimus (RAD001) in combination With lenalidomide in patients with advanced solid malignancies enriched for renal cell carcinoma. Available at http://www.clinicaltrials.gov. Last accessed 18 Mar 2011

  67. Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R (2002) A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95(4):758–765

    Article  CAS  PubMed  Google Scholar 

  68. Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13(7):1029–1035

    Article  CAS  PubMed  Google Scholar 

  69. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM (2002) A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95(8):1629–1636

    Article  CAS  PubMed  Google Scholar 

  70. Hernberg M, Virkkunen P, Bono P, Ahtinen H, Mäenpää H, Joensuu H (2003) Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21(20):3770–3776

    Article  CAS  PubMed  Google Scholar 

  71. Lawler J (1986) The structural and functional properties of thrombospondin. Blood 67(5):1197–1209

    CAS  PubMed  Google Scholar 

  72. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265(5178):1582–1584

    Article  CAS  PubMed  Google Scholar 

  73. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R (2007) Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 13(22):6689–6695

    Article  CAS  PubMed  Google Scholar 

  74. Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M (2009) Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw 20(4):225–234

    CAS  PubMed  Google Scholar 

  75. Sarker D, Molife R, Evans TRJ, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14(7):2075–2081

    Article  CAS  PubMed  Google Scholar 

  76. Angevin E, Lin C, Pande AU, Lopez JA, Gschwend J, Harzstark AL, Shi M, Anak O, Escudier BJ (2010) A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: phase I results. ASCO Meet Abstr 28(15 Suppl):3057

    Google Scholar 

  77. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grunwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15(3):286–296

    Article  CAS  PubMed  Google Scholar 

  78. Perera AD, Kleymenova EV, Walker CL (2000) Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell Carcinoma. Clin Cancer Res 6(4):1518–1523

    CAS  PubMed  Google Scholar 

  79. Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan C-X, Crawford D (2009) Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 27(34):5788–5793

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Flaig TW, Costa LJ, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ, Drabkin H (2010) Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer 103(6):796–801

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25(29):4536–4541

    Article  CAS  PubMed  Google Scholar 

  82. Hainsworth JD, Spigel DR, Sosman JA, Burris HA 3rd, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM, Greco FA (2007) Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 5(7):427–432

    Article  CAS  PubMed  Google Scholar 

  83. Srivastava M, Pollard HB (1999) Molecular dissection of nucleolin’s role in growth and cell proliferation: new insights. FASEB J 13(14):1911–1922

    CAS  PubMed  Google Scholar 

  84. Mongelard F, Bouvet P (2007) Nucleolin: a multiFACeTed protein. Trends Cell Biol 17(2):80–86

    Article  CAS  PubMed  Google Scholar 

  85. Hovanessian AG, Puvion-Dutilleul F, Nisole S, Svab J, Perret E, Deng J-S, Krust B (2000) The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res 261(2):312–328

    Article  CAS  PubMed  Google Scholar 

  86. Teng Y, Girvan AC, Casson LK, Pierce WM, Qian M, Thomas SD, Bates PJ (2007) AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res 67(21):10491–10500

    Article  CAS  PubMed  Google Scholar 

  87. Rosenberg JE, Drabkin HA, Lara P, Harzstark AL, Figlin RA, Smith GW, Erlandsson F, Laber DA (2010) A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC). ASCO Meet Abstr 28(15 Suppl):4590

    Google Scholar 

  88. Naito S, Eto M, Shinohara N, Tomita Y, Fujisawa M, Namiki M, Nishikido M, Usami M, Tsukamoto T, Akaza H (2010) Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 28(34):5022–5029

    Article  CAS  PubMed  Google Scholar 

  89. Posadas EM, Undevia S, Manchen E, Wade JL, Colevas AD, Karrison T, Vokes EE, Stadler WM (2007) A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther 6(4):490–493

    Article  CAS  PubMed  Google Scholar 

  90. Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, Fojo T (2010) A phase II clinical trial of ixabepilone (ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res 16(5):1634–1641

    Article  CAS  PubMed  Google Scholar 

  91. Blagden SP, Molife LR, Seebaran A, Payne M, Reid AH, Protheroe AS, Vasist LS, Williams DD, Bowen C, Kathman SJ, Hodge JP, Dar MM, de Bono JS, Middleton MR (2008) A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer 98(5):894–899

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  92. Burris HA 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, Ho PT, Boerner SA, Lorusso P (2010) A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 13:13

    Google Scholar 

  93. Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M, Bridge JA (2011) Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 24(3):430–442

    Article  CAS  PubMed  Google Scholar 

  94. Mariño-Enríquez A, Ou W-B, Weldon CB, Fletcher JA, Pérez-Atayde AR (2011) ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosom Cancer 50(3):146–153

    Article  PubMed  Google Scholar 

  95. Bang Y, Kwak EL, Shaw AT, Camidge DR, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Clark JW (2010) Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol (Meet Abstr) 28(18 Suppl):3

    Google Scholar 

  96. Antoniu SA (2011) Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703. Expert Opin Ther Targets 15(3):351–353

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kidney Cancer Program, Division of Genitourinary Oncology, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Sumanta Kumar Pal MD

  2. Department of Urology, Cedars Sinai Medical Center, Los Angeles, CA, USA

    David Y. Josephson MD

  3. Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Przemyslaw Twardowski MD

  4. Developmental Therapeutics Program, Division of Cancer Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA

    David I. Quinn MBBS, PhD, FRACP, FACP

Authors
  1. Sumanta Kumar Pal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Y. Josephson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Przemyslaw Twardowski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David I. Quinn MBBS, PhD, FRACP, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sumanta Kumar Pal MD .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, Division of Hematology - Oncology, University of California Davis, School of Medicine UC Davis Comprehensive Cancer center, Sacramento, California, USA

    Primo N. Lara

  2. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Eric Jonasch

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Pal, S.K., Josephson, D.Y., Twardowski, P., Quinn, D.I. (2015). Emerging Agents in Renal Cell Carcinoma. In: Lara, P., Jonasch, E. (eds) Kidney Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-17903-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17903-2_23

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17902-5

  • Online ISBN: 978-3-319-17903-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation